PHARMACEUTICAL News & Analysis

Our analyst weighs in on the proposed acquisition and Sigma’s capital raise.

But the tie-up could face significant hurdles, says Morningstar analysts.  

These wide-moat, low-uncertainty names are reliable, writes Susan Dziubinski.

Will there be a second wave? Can we avoid another shutdown? Could a treatment be used to prevent disease? Morningstar strategists respond.

A new Morningstar report identifies which big-name health companies are inoculated against environmental, social and governance risks.

These high-quality companies, including Bristol-Myers Squibb, Roche and Imperial Brands, span a broad range of sectors and represent good value at...

These industries are the most undervalued in the US healthcare sector, owing to potential drug pricing reforms coming out of Washington.

The legalisation of cannabis in Canada has boosted an industry that Morningstar forecasts will grow by nine times through 2030

Though Morningstar views the healthcare sectors in both the US and Australia as fairly valued overall, there is a handful of buying opportunities...

Rising coal prices have boosted Washington H Soul Pattinson's first-half profit, while restructuring has taken a toll on Sigma, and Brickworks sounds...